64 phenotypes from 4 alleles in 5 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Gatmem1Btlr/Gatmem1Btlr C57BL/6J-Gatmem1Btlr	abnormal enterocyte proliferation	J:252049
	decreased colon length	J:252049
	decreased creatine level	J:252049
	normal immune system phenotype	J:252049
	increased enterocyte apoptosis	J:252049
	increased physiological sensitivity to xenobiotic	J:252049
	increased susceptibility to induced colitis	J:252049
Gatmem1Btlr/Gatmm1Btlr C57BL/6J-Gatmem1Btlr/Gatmm1Btlr	decreased colon length	J:252049
	diarrhea	J:252049
	increased susceptibility to induced colitis	J:252049
	increased susceptibility to weight loss	J:252049
Gatmm1Btlr/Gatm+ C57BL/6J-Gatmm1Btlr	increased susceptibility to induced colitis	J:252049
	increased susceptibility to xenobiotic induced morbidity/mortality	J:252049
Gatmm1Btlr/Gatmm1Btlr C57BL/6J-Gatmm1Btlr	abnormal duodenum crypts of Lieberkuhn morphology	J:252049
	decreased colon length	J:252049
	decreased creatine level	J:252049
	diarrhea	J:252049
	increased enterocyte apoptosis	J:252049
	increased susceptibility to induced colitis	J:252049
	increased susceptibility to weight loss	J:252049
	increased susceptibility to xenobiotic induced morbidity/mortality	J:252049
Gatmtm1.1Isb/Gatmtm1.1Isb B6.129-Gatmtm1.1Isb	abnormal eating behavior	J:191142
	abnormal gluconeogenesis	J:191142
	abnormal glucose homeostasis	J:191142
	abnormal spermatogenesis	J:191142
	abnormal testis morphology	J:191142
	abnormal urine amino acid level	J:191142
	decreased body length	J:191142
	decreased body mass index	J:191142
	decreased body weight	J:191142
	decreased circulating cholesterol level	J:191142
	decreased circulating glucose level	J:191142
	decreased circulating insulin level	J:191142
	decreased circulating leptin level	J:191142
	decreased circulating triglyceride level	J:191142
	decreased liver triglyceride level	J:191142
	decreased locomotor activity	J:191142
	decreased subcutaneous adipose tissue amount	J:191142
	decreased susceptibility to diet-induced hepatic steatosis	J:191142
	decreased susceptibility to diet-induced obesity	J:191142
	decreased total body fat amount	J:191142
	decreased urine creatine level	J:191142
	decreased urine creatinine level	J:191142
	decreased white adipose tissue amount	J:191142
	female infertility	J:191142
	normal growth/size/body region phenotype	J:191142
	normal homeostasis/metabolism phenotype	J:191142
	hypotonia	J:191142
	improved glucose tolerance	J:191142
	increased adipocyte glucose uptake	J:191142
	increased muscle cell glucose uptake	J:191142
	male infertility	J:191142
	scoliosis	J:191142
Gatmtm1b(KOMP)Wtsi/Gatmtm1b(KOMP)Wtsi C57BL/6N-Gatmtm1b(KOMP)Wtsi/Ieg	abnormal QT variability	J:211773
	abnormal sinus arrhythmia	J:211773
	cardiovascular system phenotype	J:211773
	decreased circulating alkaline phosphatase level	J:211773
	decreased circulating cholesterol level	J:211773
	decreased exploration in new environment	J:211773
	decreased food intake	J:211773
	decreased grip strength	J:211773
	decreased heart rate	J:211773
	decreased locomotor activity	J:211773
	decreased prepulse inhibition	J:211773
	decreased red blood cell distribution width	J:211773
	decreased respiratory quotient	J:211773
	female infertility	J:211773
	increased circulating amylase level	J:211773
	increased circulating aspartate transaminase level	J:211773
	increased circulating potassium level	J:211773
	increased heart rate variability	J:211773
	increased mean corpuscular hemoglobin	J:211773
	male infertility	J:211773
	prolonged QRS complex duration	J:211773
	prolonged QT interval	J:211773
	prolonged RR interval	J:211773
	prolonged ST segment	J:211773
	thrombocytopenia	J:211773